Semaglutide and tirzepatide are the two big GLP-1-class molecules. The structural difference — tirzepatide also activates GIP — sounds academic until you see the outcomes: tirzepatide averages up to 22.5% weight loss against semaglutide's 14.9%. For anyone eating on these drugs, that gap means the tirzepatide side has less appetite, more nausea risk, and a harder job protecting muscle.
| A | B | |
|---|---|---|
| Targets | GLP-1 only | GLP-1 + GIP |
| Brands | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| Average weight loss | 14.9% (STEP 1) | Up to 22.5% (SURMOUNT-1) |
| Nausea reported | ~44% at top dose | ~25-30% across doses |
| Food rules | Protein-first framework | Same framework, stricter execution |
The same judgment framework runs across this site — protein, fiber and how heavy a food sits on a slow stomach.
| Easy on both | Risky on both |
|---|---|
|
|
Tirzepatide. Stronger appetite suppression means each meal carries more responsibility: protein must come first, portions must be smaller, and fatty foods are riskier.
The added GIP activation amplifies appetite and fullness signals beyond what GLP-1 alone does, roughly translating to 5-7 more percentage points of weight loss in trials.
Yes — the judgment framework is identical because the physiology is the same class. Lean protein, vegetables, legumes and whole grains score well on both; fried foods, sugary drinks and heavy sauces are risky on both.
This comparison presents published trial data (STEP, SURMOUNT, SCALE, OASIS 4) and FDA label information for reference. It is not medical advice and does not recommend any medication. Prescription decisions belong to you and your healthcare provider.